Delving into the Latest Updates on Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE(Thomas Jefferson University) with Synapse

Overview

Basic Info

Drug Type

Vaccine

Synonyms-

Target

GC-C

Mechanism

GC-C antagonists(Heat-stable enterotoxin receptor antagonists)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Thomas Jefferson University

Active Organization

Thomas Jefferson University

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This phase IIA trial investigates the side effects of Ad5.F35-hGCC-PADRE vaccine and to see how well it works in treating patients with gastrointestinal adenocarcinoma. Ad5.F35-hGCC-PADRE vaccine may help to train the patient's own immune system to identify and kill tumor cells and prevent it from coming back.

Start Date10 Nov 2020

Sponsor / Collaborator

Thomas Jefferson University

100 Clinical Results associated with Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE(Thomas Jefferson University)

Login to view more data

100 Translational Medicine associated with Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE(Thomas Jefferson University)

Login to view more data

100 Patents (Medical) associated with Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE(Thomas Jefferson University)

Login to view more data

100 Deals associated with Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE(Thomas Jefferson University)

Login to view more data